Pharmaceutical Grade CAS 47931-85-1 Calcitonin Salmon Treatment Osteoporosis Calcitonin Salmon Raw Powder Calcitonin Salmon

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Calcitonin Salmon
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Calcitonin Salmon
• Name: Calcitonin Salmon Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical;Treatment Osteoporosis
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 47931-85-1
• Mf: C145h240n44o48s2
• MW: 3431.8531
• Density: 1.54±0.1 g/cm3
• Refractive Index: 1.676
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical Grade CAS 47931-85-1 Calcitonin Salmon Treatment Osteoporosis Calcitonin Salmon Raw Powder Calcitonin Salmon

Product Description

Product Details

Product name	Salmon Calcitonin
Appearance	White powder
CAS NO.	47931-85-1
MF	C145H240N44O48S2
MW	3431.8531

Calcitonin, Salmon is a calcium regulating hormone secreted from mammalian thyroid parafollicular cells and in non-mammalian species from the ultimobranchial gland. Calcitonins are single chain polypeptides containing 32 amino-acid residues, showing hypocalcaemic and hypophosphatemic action, with amino-acid structure differing amongst mammalian species. Salmon calcitonin(salcatonin is the synthetic analogue) shows a markedly different sequence to that of the higher vertebrates as well as more potent activity. Eel calcitonin (Elcatonin) possesses a similar amino acid to that of the salmon form but is more stable than natural calcitonins because of the absence of disulfide bridges.

Application&Function

-Treatment of postmenopausal women with osteoporosis at high risk for fracture
-Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture
-Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture

Salmon calcitonin, inhibit the activity of osteoclasts,Inhibit bone salt dissolving, prevent bone calcium release;Improve bone mineral density, effectively relieve pain symptoms;Reduce the risk of fractures;Lower blood calcium.

1. Disabled or inability to use early and late postmenopausal osteoporosis and senile osteoporosis in combination with conventional estrogen and calcium preparations.

2. Hypercalcemia secondary to bone metastasis of breast cancer, lung cancer or kidney cancer, myeloma and other malignant tumors.

3 osteoarthritis.

4. Hyperparathyroidism, lack of activity or vitamin D poisoning (including acute or chronic poisoning).

5. Painful neurotrophic or Sudeck's disease.

Specification